Published on: 3 August 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer more
Published on: 31 July 2020 FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma more
